NCT01521611View on ClinicalTrials.gov

Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

July 1, 2017

Study Completion Date

July 1, 2018

Conditions
Acute LeukaemiaChronic LeukaemiaMyelomaLymphoma
Interventions
RADIATION

Targeted radiotherapy

Yttrium-90 labelled anti-CD66 monoclonal antibody.

Trial Locations (2)

SO16 6YD

Southampton University Hospitals NHS Trust, Southampton

Unknown

Royal Free Hospital and University College London, London

All Listed Sponsors
collaborator

Royal Free and University College Medical School

OTHER

lead

University Hospital Southampton NHS Foundation Trust

OTHER

NCT01521611 - Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy | Biotech Hunter | Biotech Hunter